Efficacy and safety of a pyrotinib-based regimen in non-small cell lung cancer patients harboring HER2 alterations: A real-world retrospective study

被引:1
作者
Wang, Xiangling [1 ]
Wang, Jian [1 ]
Chu, Yunxia [1 ]
Hao, Jing [1 ]
机构
[1] Shandong Univ, Dept Med Oncol, Qilu Hosp, Jinan, Shandong, Peoples R China
关键词
HER2; alteration; non-small cell lung cancer; pyrotinib; KINASE INHIBITORS; MUTATIONS;
D O I
10.4103/jcrt.jcrt_1268_23
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background:Pyrotinib, a novel irreversible pan-HER tyrosine kinase inhibitor, has been approved for the treatment of HER2-positive metastatic breast cancer in China. The aim of this study was to evaluate the efficacy and safety of pyrotinib in advanced nonsmall cell lung cancer (NSCLC) patients with HER2 alterations in real-world practice.Materials and Methods:A retrospective analysis of advanced NSCLC with HER2 mutations or amplifications who received pyrotinib-based treatment at the Qilu Hospital in Shandong University was performed. The primary end points were objective response rate and safety. The secondary end points were progression-free survival, disease control rate, and overall survival.Results:Twenty three eligible patients from a single center were enrolled between June 2019 and March 2023; among them, 21 had HER2 mutation and two harbored HER2 amplification. Evaluation of the efficacy in 21 patients revealed an objective response rate of 28.6% (6/21; 95% confidence interval [CI]: 7.5%-49.6%) and disease control rate of 85.7% (18/21). The median progression-free survival and overall survival were 7.7 months (95% CI: 6.07-9.33) and 20.8 months (95% CI: 8.42-33.18), respectively. The most common adverse events (AEs) included diarrhea (n = 14, 60.9%), nausea (n = 5, 21.7%), and liver dysfunction (n = 5, 21.7%). Seven patients (7/23, 30.4%) had grade 3-4 AE; no grade 5 AE was observed. Furthermore, one patient (1/23, 4.3%) experienced dose withdrawal and two (2/23, 8.7%) presented with dose reduction symptoms.Conclusion:Pyrotinib-based therapy showed promising antitumor activity and acceptable safety in advanced NSCLC patients with HER2 alterations.
引用
收藏
页码:1663 / 1668
页数:6
相关论文
共 31 条
  • [1] Besse B., 2014, ANN ONCOL, V25, pv1, DOI [10.1093/annonc/mdu438.47, DOI 10.1093/ANNONC/MDU438.47]
  • [2] Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma
    De Greve, Jacques
    Moran, Teresa
    Graas, Marie-Pascale
    Galdermans, Daniella
    Vuylsteke, Peter
    Canon, Jean-Luc
    Schallier, Denis
    Decoster, Lore
    Teugels, Erik
    Massey, Dan
    Chand, Vikram K.
    Vansteenkiste, Johan
    [J]. LUNG CANCER, 2015, 88 (01) : 63 - 69
  • [3] Afatinib in NSCLC With HER2 Mutations: Results of the Prospective, Open-Label Phase II NICHE Trial of European Thoracic Oncology Platform (ETOP)
    Dziadziuszko, Rafal
    Smit, Egbert F.
    Dafni, Urania
    Wolf, Juergen
    Wasag, Bartosz
    Biernat, Wojciech
    Finn, Stephen P.
    Kammler, Roswitha
    Tsourti, Zoi
    Rabaglio, Manuela
    Ruepp, Barbara
    Roschitzki-Voser, Heidi
    Stahel, Rolf A.
    Felip, Enriqueta
    Peters, Solange
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (06) : 1086 - 1094
  • [4] Poziotinib for Patients With HER2 Exon 20 Mutant Non-Small-Cell Lung Cancer: Results From a Phase II Trial
    Elamin, Yasir Y.
    Robichaux, Jacqulyne P.
    Carter, Brett W.
    Altan, Mehmet
    Gibbons, Don L.
    Fossella, Frank, V
    Lam, Vincent K.
    Patel, Anisha B.
    Negrao, Marcelo, V
    Le, Xiuning
    Mott, Frank E.
    Zhang, Jianjun
    Feng, Lei
    Blumenschein, George, Jr.
    Tsao, Anne S.
    Heymach, John, V
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 702 - 709
  • [5] Mutation Variants and Co-Mutations as Genomic Modifiers of Response to Afatinib in HER2-Mutant Lung Adenocarcinoma
    Fang, Wenfeng
    Zhao, Shen
    Liang, Ying
    Yang, Yunpeng
    Yang, Lin
    Dong, Xiaorong
    Zhang, Li
    Tang, Yong
    Wang, Shoufeng
    Yang, Yang
    Ma, Xiaoyan
    Wang, Minghui
    Wang, Wenjing
    Zhao, Songhui
    Wang, Kai
    Gao, Song
    Zhang, Li
    [J]. ONCOLOGIST, 2020, 25 (03) : E545 - E554
  • [6] Neratinib Temsirolimus in HER2-Mutant Lung Cancers: An International, Randomized Phase II Study
    Gandhi, Leena
    Besse, Benjamin
    Mazieres, Julien
    Waciar, Saiama
    Cortot, Alexis
    Barlesi, Fabrice
    Quoix, Elisabeth
    Otterson, Gregory
    Ettinger, David
    Horn, Leora
    Moro-Sibilot, Denis
    Socinski, Mark
    Gold, Kathryn
    Gray, Jhanelle
    Oton, Ana
    Heist, Rebecca Suk
    Costa, Daniel
    Mcculloch, Leanne
    Bebchuk, Judith
    Bryce, Richard
    Kris, Mark
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S358 - S359
  • [7] Poziotinib in Non-Small-Cell Lung Cancer Harboring HER2 Exon 20 Insertion Mutations After Prior Therapies: ZENITH20-2 Trial
    Le, Xiuning
    Cornelissen, Robin
    Garassino, Marina
    Clarke, Jeffrey M.
    Tchekmedyian, Nishan
    Goldman, Jonathan W.
    Leu, Szu-Yun
    Bhat, Gajanan
    Lebel, Francois
    Heymach, John, V
    Socinski, Mark A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (07) : 710 - 718
  • [8] Somatic mutations of ERBB2 kinase domain in gastric, colorectal, and breast carcinomas
    Lee, JW
    Soung, YH
    Seo, SH
    Kim, SY
    Park, CH
    Wang, YP
    Park, K
    Nam, SW
    Park, WS
    Kim, SH
    Lee, JY
    Yoo, NJ
    Lee, SH
    [J]. CLINICAL CANCER RESEARCH, 2006, 12 (01) : 57 - 61
  • [9] Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer
    Li, Bob T.
    Smit, Egbert F.
    Goto, Yasushi
    Nakagawa, Kazuhiko
    Udagawa, Hibiki
    Mazieres, Julien
    Nagasaka, Misako
    Bazhenova, Lyudmila
    Saltos, Andreas N.
    Felip, Enriqueta
    Pacheco, Jose M.
    Perol, Maurice
    Paz-Ares, Luis
    Saxena, Kapil
    Shiga, Ryota
    Cheng, Yingkai
    Acharyya, Suddhasatta
    Vitazka, Patrik
    Shahidi, Javad
    Planchard, David
    Janne, Pasi A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (03) : 241 - 251
  • [10] Discovery and development of pyrotinib: A novel irreversible EGFR/HER2 dual tyrosine kinase inhibitor with favorable safety profiles for the treatment of breast cancer
    Li, Xin
    Yang, Changyong
    Wan, Hong
    Zhang, Ge
    Feng, Jun
    Zhang, Lei
    Chen, Xiaoyan
    Zhong, Dafang
    Lou, Liguang
    Tao, Weikang
    Zhang, Lianshan
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2017, 110 : 51 - 61